Compare ARLP & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | PGEN |
|---|---|---|
| Founded | 1971 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1999 | 2013 |
| Metric | ARLP | PGEN |
|---|---|---|
| Price | $25.83 | $6.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $31.17 | $13.65 |
| AVG Volume (30 Days) | 276.3K | ★ 4.6M |
| Earning Date | 10-26-2026 | 11-12-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $2,002,857,000.00 | $230,981,000.00 |
| Revenue This Year | $1.85 | $2,365.68 |
| Revenue Next Year | $3.75 | $85.75 |
| P/E Ratio | ★ $10.68 | $220.17 |
| Revenue Growth | ★ 11.50 | N/A |
| 52 Week Low | $23.01 | $3.04 |
| 52 Week High | $29.45 | $8.98 |
| Indicator | ARLP | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 36.29 |
| Support Level | $24.30 | $6.08 |
| Resistance Level | $26.42 | $7.44 |
| Average True Range (ATR) | 0.35 | 0.44 |
| MACD | 0.16 | -0.17 |
| Stochastic Oscillator | 89.54 | 2.37 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties, and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex, and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II, and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties have included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.